Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO “Top 5” List Turns Up Rhetorical Heat On Cancer Drug Prices

This article was originally published in RPM Report

Executive Summary

“Financial toxicity” should be considered by oncologists in use of new, targeted therapies, oncology association says. A new list of practices to avoid puts drug costs more squarely in crosshairs than first version in 2012.

You may also be interested in...



Cost-Consciousness Raising: Adding Value To Cancer Drug Development

As the market attempts to reconcile the high prices of revolutionary new cancer therapies with pressure to control rising health care costs, oncology associations call for new drugs to demonstrate clinical value in addition to meeting FDA’s standards of safety and efficacy. Can “continuous learning systems” help?

Cost-Consciousness Raising: Adding Value To Cancer Drug Development

As the market attempts to reconcile the high prices of revolutionary new cancer therapies with pressure to control rising health care costs, oncology associations call for new drugs to demonstrate clinical value in addition to meeting FDA’s standards of safety and efficacy. Can “continuous learning systems” help?

Ending “Buy-And-Bill” in Oncology: The Question is How, Not If

The public policy debate over affordability of cancer care is approaching consensus on the need to end the “buy-and-bill” model for chemotherapy. How, and how fast, are the key remaining questions. For biopharma manufacturers, there are good reasons to embrace the change.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel